Neuroleptic-induced Parkinsonism: Clinicopathological study

Movement Disorders

Volumn 31, Issue 3, 2016, Pages 360-365

  Shuaib, Umar A ^a   Rajput, Ali H ^b   Robinson, Christopher A ^b   Rajput, Alex ^b  

^a ROYAL UNIVERSITY HOSPITAL   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Drug induced; Neuroleptic induced; Parkinsonism; Pathology; Substantia nigra

Indexed keywords

BENZATROPINE; CARBIDOPA PLUS LEVODOPA; CHLORPROMAZINE; DOPAMINE RECEPTOR BLOCKING AGENT; HALOPERIDOL; LEVODOPA; LITHIUM; LORAZEPAM; METOCLOPRAMIDE; PHENOTHIAZINE; PROPRANOLOL; QUETIAPINE; RISPERIDONE; RIVASTIGMINE; SELEGILINE; TRIHEXYPHENIDYL; DOPAMINE RECEPTOR STIMULATING AGENT; NEUROLEPTIC AGENT;

ADULT; AGED; ARTICLE; AUTOPSY; BIPOLAR DISORDER; CASE REPORT; CLINICAL FEATURE; CONFUSION; DEPRESSION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GASTROESOPHAGEAL REFLUX; HALLUCINATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MIDDLE AGED; NERVE CELL DEGENERATION; NEUROLEPTIC INDUCED PARKINSONISM; PARKINSONISM; PRIORITY JOURNAL; STOMACH PAIN; SUBSTANTIA NIGRA; TREMOR; CHEMICALLY INDUCED; LEWY BODY; PARKINSON DISEASE; PATHOLOGY;

AGED; ANTIPSYCHOTIC AGENTS; DOPAMINE AGENTS; HUMANS; LEVODOPA; LEWY BODIES; MALE; MIDDLE AGED; PARKINSON DISEASE, SECONDARY; SUBSTANTIA NIGRA;

EID: 84952332730     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26467     Document Type: Article

References (33)

1. Lopez-Sendon J, Mena MA, de Yebenes JG. Drug-induced parkinsonism. Expert Opin Drug Saf 2013;12:487-496.
2. Friedman JH. Drug-Induced parkinsonism. In: Lang AE, Weiner WJ, eds. Drug-Induced Movement Disorders. 1st ed. Mount Kisco, NY: Futura; 1992:41-83.
3. Barbosa MT, Caramelli P, Maia DP, et al. Parkinsonism and Parkinson's disease in the elderly: a community-based survey in Brazil (the Bambuí Study). Mov Disord 2006;21:800-808.
4. Rajput AH, Offord KP, Beard CM, Kurland LT. Epidemiology of parkinsonism: incidence, classification, and mortality. Ann Neurol 1984;16:278-282.
5. Marti Masso JF, Poza JJ. Drug-induced or aggravated parkinsonism: clinical signs and the changing pattern of implicated drugs. Neurologia 1996;11:10-15.
6. Llau ME, Nguyen L, Senard JM, et al. Drug-induced parkinsonian syndromes: a 10-year experience at a regional center of pharmaco-vigilance. Rev Neurol (Paris) 1994;150:757-762.
7. Hardie RJ, Lees AJ. Neuroleptic-induced Parkinson's syndrome: clinical features and results of treatment with levodopa. J Neurol Neurosurg Psychiatry 1988;51:850-854.
8. Friedman JH, Trieschmann ME, Fernandez HH. Drug-induced parkinsonism. In: Factor SA, Lang AE, Weiner WJ, eds. Drug Induced Movement Disorders. 2nd ed. Blackwell Futura; 2005:103-139.
9. Remington G, Kapur S. The pharmacology of typical and atypical antipsychotics. In: Factor SA, Lang AE, Weiner WJ, eds. Drug Induced Movement Disorders. 2nd ed. Blackwell Futura; 2005:55-71.
10. Rajput AH, Rozdilsky B, Hornykiewicz O, Shannak K, Lee T, Seeman P. Reversible drug-induced parkinsonism: clinicopathologic study of two cases. Arch Neurol 1982;39:644-646.
11. Bower JH, Dickson DW, Taylor L, Maraganore DM, Rocca WA. Clinical correlates of the pathology underlying parkinsonism: a population perspective. Mov Disord 2002;17:910-916.
12. 23I]-FP/CIT SPECT imaging for distinguishing drug-induced parkinsonism from Parkinson's disease. Mov Disord 2006;21:510-514.
13. Tinazzi M, Margante F, Matinella A, et al. Imaging of the dopamine transporter predicts pattern of disease progression and response to levodopa in patients with schizophrenia and parkinsonism: a 2-year follow-up multicenter study. Schizophr Res 2014;152:344-349.
14. Rajput AH, Voll A, Rajput ML, Robinson CA, Rajput A. Course in Parkinson's disease subtypes: a 39-year clinicopathological study. Neurology 2009;73:206-212.
15. Webster DD. Critical analysis of disability in Parkinson's disease. Mod Treat 1968;5:257-282.
16. Fahn S, Elton RL, UPDRS Development Committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne D, Goldstein M, eds. Recent Developments in Parkinson's Disease, 2 ed. Florham Park, NJ: Macmillan Healthcare Information; 1987:153-305.
17. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967;17:427-442.
18. Montine TJ, Phelps CH, Beach TG, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol 2012;123:1-11.
19. Ehringer H, Hornykiewicz O. Distribution of noradrenaline and dopamine (3-hydroxytyramine) in human brain: their behaviour in extrapyramidal system diseases. Klin Wochenschr 1960;38:1236-1239.
20. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999;56:33-39.
21. Jellinger K. The pathology of parkinsonism. In: Marsden CD, Fahn S, eds. Movement Disorders 2. London: Butterworths; 1987:124-165.
22. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G. Positron emission tomogrphic analysis of central D1 and D2 receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 1992;49:538-544.
23. Erro R, Bhatia KP, Tinazzi M. Parkinsonism following neuroleptic exposure: a double-hit hypothesis? Mov Disord 2015;30:780-785.
24. Morley J, Pawlowski S, Pantelyat A, Kesari A, Maina I, Duda J. Olfactory impairment and other features of Parkinson disease that predict persistent drug-induced parkinsonism. Neurology 2014;82:P3.080.
25. 123l-metaiodobenzylguanidine (MIBG) scintigraphy and dopamine transporter (DAT) positron emission tomography (PET) predicts prognosis in drug-induced Parkinsonism (DIP): a 2-year follow-up study. Arch Gerontol Geriatr 2013;56:124-128.
26. Brigo F, Error R, Marangi A, Bhatia K, Tinazzi M. Differentiating drug-induced parkinsonism from Parkinson's disease: an update on non-motor symptoms and investigations. Parkinsonism Relat Disord 2014;20:808-814.
27. Alvord EC, Jr., Forno LS, Kusske JA, Kauffman RJ, Rhodes JS, Goetowski CR. The pathology of parkinsonism: a comparison of degenerations in cerebral cortex and brainstem. In: McDowell FH, Barbeau A, eds. Advances in Neurology, 5. New York: Raven; 1974:175-193.
28. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114:2283-2301.
29. Pakkenberg B, Moller A, Gundersen HJ, Mouritzen Dam A, Pakkenberg H. The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson's disease estimated with an unbiased stereological method. J Neurol Neurosurg Psychiatry 1991;54:30-33.
30. Khot V, Egan MF, Hyde TM, Wyatt RJ. Neuroleptics and classic tardive dyskinesia. In: Factor SA, Lang AE, Weiner WJ, eds. Drug Induced Movement Disorders. 2nd ed. Blackwell Futura; 2005:121-166.
31. Sethi KD, Zamrini EY. Asymmetry in clinical featurse of drug-induced parkinsonism. J Neuropsychiatry Clin Neurosci 1990;2:64-66.
32. Magnus RV. A comparison of biperiden hydrochloride (Akineton) benzhexol (Artane) in the treatment of drug-induced parkinsonism. J Int Med Res 1980;8:343-346.
33. Fann WE, Lake CR. Amantadine vs trihexyphenidyl in the treatment of neuroleptic-induced parkinsonism. Am J Psychiatry 1976;133:940-943.